UCB's Bimzelx continues winning streak with victory over AbbVie's Skyrizi

11th March 2026 Uncategorised 0

After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis in a head-to-head phase 3b study.

More: UCB's Bimzelx continues winning streak with victory over AbbVie's Skyrizi
Source: fierce